4886 — ASKA Pharmaceutical Holdings Co Income Statement
0.000.00%
Last trade - 00:00
- ¥64bn
- ¥54bn
- ¥60bn
- 66
- 62
- 98
- 92
2019 March 31st | 2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | Yuho | Yuho | Tanshin | Yuho | Yuho |
Standards: | JAS | JAS | — | JAS | JAS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 46,706 | 52,542 | 55,181 | 56,607 | 60,461 |
Cost of Revenue | |||||
Gross Profit | 18,892 | 24,017 | 25,383 | 26,352 | 28,585 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 45,127 | 51,848 | 51,580 | 59,954 | 55,353 |
Operating Profit | 1,579 | 694 | 3,601 | -3,347 | 5,108 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 1,883 | 901 | 3,575 | 6,163 | 5,357 |
Provision for Income Taxes | |||||
Net Income After Taxes | 1,745 | 649 | 2,714 | 4,290 | 4,239 |
Net Income Before Extraordinary Items | |||||
Net Income | 1,745 | 649 | 2,714 | 4,290 | 4,239 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 1,744 | 649 | 2,713 | 4,290 | 4,238 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 61.8 | 43.6 | 95.9 | 121 | 152 |
Dividends per Share | |||||
Special Dividends per Share |